Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of a...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:FARON
localefi
websitehttps://www.faron.com/
ipo_date2015-11-17
primary_stock_msh_idLSE:FARN
source_refd5a671e4-caf8-4b52-bf77-20d46334cd50
products_or_servicesImmunotherapies targeting cancer, specifically bexmarilimab which targets the Clever-1 receptor on macrophages.